Clinical Trials
- Gastrointestinal Oncology
- Clinical Trials
Thank you for your interest in GI clinical trials at UCSF.
Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial.
Please see the links below for current open trials at UC San Francisco.
COLORECTAL
METASTATIC
CC#16702: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers (MSI-H colorectal carcinomas)
Contact: Katrina Sadang (415) 476-2958:KatrinaGrace.Sadang@ucsf.edu
CC#16706: Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms
Contact: Jeremy Burbanks-Ivey (415) 502-4727:Jeremy.Burbanks-Ivey@ucsf.edu
NEOADJUVANT RECTAL
Alliance N1048: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
Contact: Samantha Maisel (415) 502-3310: Samantha.Maisel@ucsf.edu
SURVIVORSHIP
CC#164511 Survivor Choices for Eating and Drinking (Succeed) - Colorectal Cancer
Contact: Andrea Bocobo (415) 476-3755:AndreaGrace.Bocobo@ucsf.edu
EARLY PHASE
CC#15956: A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed against CD47, in Subjects with Advanced Solid and Hematologic Cancers
Contact: Roh Rahimi (415) 885-3728: Roshun.Rahimi@ucsf.edu
CC# 159518: A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with a Solid Tumor Cancer
Contact: Armand Harb (415) 353-7381: Armand.Harb@ucsf.edu
AMC095: A phase 1 study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
Contact: Erika Zigman (415) 514-6248: Erika.Zigman@ucsf.edu
CC#159516: A phase 1b, Open-Label Study of Alpelisib (BYL719) in Combination with Cisplatin in Patients with HPV+ Solid Tumor Malignancies
Contact: Ann Chan (415) 885-3670: Ann.Chan@ucsf.edu
CC#16954: Phase 1/2 Study of CORT125134 in Combination with Nab-paclitaxel in Patients with Solid Tumors.
Contact: Erika Zigman (415) 514-6248: Erika.Zigman@ucsf.edu
CC159520: A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors
Contact: Claire Hooker (415) 885-3724 : Claire.Hooker@ucsf.edu
CC#16955: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-like Protein 3-Expressing Advanced Solid Tumors
Contact: Emily Boyd (415)-514-6638: Emily.Boyd2@ucsf.edu
CC#169514: A Phase 1 Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR1-4 Kinase Inhibitor, in Adult Patients with Advanced Solid Tumors, followed by an Expansion Cohort in Patients with FGFR1, 2, 3, or 4 Genetic Alterations
Contact: Ann Chan (415) 885-3670: Ann.Chan@ucsf.edu
CC#169516 : A Phase I/II, Multicenter, Open-Label Study of MAK683 in Adult Patients With Advanced Malignancies
Contact: Emily Boyd (415)-514-6638: Emily.Boyd2@ucsf.edu
CC#169517: A Phase 1 Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer
Contact: Phu Lam (415) 514-6363: Phu.Lam@ucsf.edu
CC#169518: Phase 1 Clinical Trial of VX-970 in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors
Contact: Phu Lam (415) 514-6363: Phu.Lam@ucsf.edu
CC#169519: A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (only SCLC and TNBC)
Contact: Erika Zigman (415) 514-6248: Erika.Zigman@ucsf.edu
CC#169521: Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair (Note: restricted to patients with defects in the following molecules: BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, RAD54L)
Contact: Armand Harb (415) 353-7381: Armand.Harb@ucsf.edu
CC#17951: A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib (RXDX-101) in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2, NTRK3, ROS1 or ALK Molecular Alterations
Contact: Claire Hooker (415) 885-3724: Claire.Hooker@ucsf.edu
CC#17953: A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients with Solid Tumors
Contact: Phu Lam (415) 514-6363: Phu.Lam@ucsf.edu
GASTRO ESOPHAGEAL
CC#16459: A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer
Contact Paige Steiding (415) 514-6314: Paige.Steiding@ucsf.edu
CC#17701: A Pilot Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers
Contact: Christopher Wong (415) 476-1044:Christopher.Wong@ucsf.edu
HEPATOCELLULAR and BILIARY TRACT
CC#133526: A Pilot Study of PET/MRI Localization of Ytrrium-90 Microspheres Following Hepatic Radioembolization in Patients with Liver Malignancies
Contact: Curt Johanson (415) 353-2310: Curt.Johanson@ucsf.edu
CC#16451: A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremeliumumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma
Contact: Trang Nguyen (415) 353-9544: TrangX.Nguyen@ucsf.edu
CC#154524: A Phase II Trial of Pembrolizumab (MK-3475) with GM-CSF Induction in Advanced Biliary Cancers
Contact: Emily Mitchell (415) 476-5442: Emily.Mitchell@ucsf.edu
CC#164514: Phase I Dose-Escalating Study of Combining Tirapazamine and Transarterial Embolization in Hepatocellular Carcinoma
Contact: Melanie Regan (415) 514-8995:Melanie.Regan@ucsf.edu
CC#16708: A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC)
Contact: Jeremy Burbanks-Ivey (415) 502-4727:Jeremy.Burbanks-Ivey@ucsf.edu
CC#17451: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation
Contact: Lillian Jahan (415) 502-4174: Lillian.Jahan@ucsf.edu
CC#17457: A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities
Contact: Maddy Griffith (415) 476-7974: Madeline.Griffith@ucsf.edu
CC#174523: A Multicenter Pilot Study of the Safety, Efficacy, and Immune Cell Profiling in Advanced Hepatocellular Carcinoma (HCC) Patients Treated with the Combination of Sorafenib plus Nivolumab as First-Line of Systemic Therapy
Contact: Maddy Griffith (415) 476-7974: Madeline.Griffith@ucsf.edu
IMMUNOTHERAPY
CC#16702: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers (MSI-H colorectal carcinomas)
Contact: Katrina Sadang (415) 476-2958:KatrinaGrace.Sadang@ucsf.edu
CC#16706: Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms (Colorectal & Pancreatic)
Contact: Jeremy Burbanks-Ivey (415) 502-4727:Jeremy.Burbanks-Ivey@ucsf.edu
CC#16708: A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC)
Contact: Jeremy Burbanks-Ivey (415) 502-4727:Jeremy.Burbanks-Ivey@ucsf.edu
CC#17701: A Pilot Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers
Contact: Christopher Wong (415) 476-1044:Christopher.Wong@ucsf.edu
CC#17709: Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Contact: Andrew Chon (415) 476-2351: Andrew.Chon@ucsf.edu
NEUROENDOCRINE TUMORS
CC#16455: Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients with Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy
Contact: Bryant Chee (415) 353-7145: Bryant.Chee@ucsf.edu
CC#169524: A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
Contact: Claire Hooker (415)-885-3724: Claire.Hooker@ucsf.edu
CC#16955: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-like Protein 3-Expressing Advanced Solid Tumors
Contact: Emily Boyd (415)-514-6638: Emily.Boyd2@ucsf.edu
CC#17455: Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
Contact: Bryant Chee (415) 353-7145: Bryant.Chee@ucsf.edu
CC#17459: Phase II Randomized Embolization Trial for Neuroendocrine Tumor Metastases To The Liver (RETNET)
Contact: Melanie Regan (415) 514-8995:Melanie.Regan@ucsf.edu
NON-THERAPEUTIC
CC#154520: Lifestyle and Patient Outcomes after Gastrointestinal Cancer: A Prospective Cohort Study (LOGIC)
Contact: Andrea Bocobo (415) 476-3755:AndreaGrace.Bocobo@ucsf.edu
CC#164511: Survivor Choices for Eating and Drinking (SUCCEED) Colorectal Cancer
Contact: Andrea Bocobo (415) 476-3755:AndreaGrace.Bocobo@ucsf.edu
CC#174525: Self-Monitoring and Reminder Texts for Physical Activity After Cancer II (Smart Pace II)
Contact: Paige Steiding (415) 514-6314: Paige.Steiding@ucsf.edu
PANCREATIC
CC#144515: A Phase II Study of PEGPH20, Gemcitabine Plus Nab-Paclitaxel in Patients With Upfront or Borderline Resectable Pancreatic Cancer
Contact: Louis Wong (415) 514-8101: Louis.Wong@ucsf.edu
CC#164518: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Contact: Louis Wong (415) 514-8101: Louis.Wong@ucsf.edu
CC#16706: Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms
Contact: Jeremy Burbanks-Ivey (415) 502-4727:Jeremy.Burbanks-Ivey@ucsf.edu
CC#17709: Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Contact: Andrew Chon (415) 476-2351: Andrew.Chon@ucsf.edu
CC#174512: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MORPHEUS-Pancreatic Cancer)
Contact: Shohei Burns (415) 514-6258: Shohei.Burns@ucsf.edu
**************************************************
**TO BE OPENED WITHIN 3 MONTHS**
CC#17705: A Pilot Study of Pembrolizumab and Liver-Directed Therapy For Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases
Contact: Andrew Chon (415) 476-2351: Andrew.Chon@ucsf.edu
CC#174517: Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer
Contact: Julia Whitman (415) 353-7683: Julia.Whitman@ucsf.edu
CC#174528: A Study of Nivolumab in Combination With Trametinib or Without Ipilimumab in Participants With Previously Treated Metastatic Colorectal Cancers
Contact: Samantha Maisel (415) 502-3310: Samantha.Maisel@ucsf.edu
CC#174532: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA)
Contact: Maddy Griffith (415) 476-7974: Madeline.Griffith@ucsf.edu
CC#17955: A Phase 1, Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and c- Met Dysregulation
Contact: Jenna Zhang (415) 353-8337: Jenna.Zhang@ucsf.edu
For information on Early Phase clinical trials not listed please contact:
Kamran Abri Lavasani (415) 514-6245: Kamran.AbriLavasani@ucsf.edu
For information on Immunotherapy trials not listed please contact: Andrew Chon (415) 476-2351: Andrew.Chon@ucsf.edu